Inspirna
Latest round
- Series D
Last raised
- Jun 2022
Total raised
- $136M
Investors
- 12
About Inspirna
Inspirna Inc.Founded in 2010 and headquartered in New York, US, Inspirna Inc. specializes in cancer therapeutics. The CEO and co-founder, Masoud Tavazoie, has previously been involved in the biotechnology sector, contributing to the strategic direction of the company.Inspirna, Inc. focuses on developing first-in-class cancer therapeutics aimed at addressing previously untreatable common cancers through its proprietary RNA-DRIVEr™ platform. The company's main products currently under development include two oral small molecules: ompenaclid (RGX-202), which is in Phase 2 trials targeting RAS mutant colorectal cancer, and abequolixron (RGX-104), which is in Phase 1b/2 trials for non-small cell lung cancer and endometrial cancer. Ompenaclid works as an inhibitor of SLC6A8, inducing apoptosis in colorectal cancer cells, while abequolixron acts as an activator of LXR/APOE, inhibiting tumor angiogenesis and enhancing the immune response. Additionally, Inspirna is developing RGX-019-MMAE, a monoclonal antibody-drug conjugate targeting MERTK to selectively eliminate cancer cells.Inspirna's revenue model is primarily centered around partnerships and collaborations with larger pharmaceutical companies, focusing on co-development and licensing agreements for its therapeutic candidates.00 mn upfront payment for an exclusive license and co-development option for ompenaclid. This transaction structure indicates that Inspirna may engage in negotiations with other global pharmaceutical companies as well, providing pathways for additional revenue through collaborations. The company’s flagship products, namely ompenaclid and abequolixron, are anticipated to generate revenue through sales to healthcare providers, hospitals, and oncologists who will incorporate these innovative therapies into their treatment regimens.In June 2022, Inspirna Inc. Inspirna plans to expand its product offerings and aims to launch ompenaclid and abequolixron into new markets, specifically targeting North America and Europe by 2025. The successful development and market approval of these therapies will significantly enhance its revenue potential.
Who invested in Inspirna
12 investors across 4 rounds
See all investors in Inspirna
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Inspirna
Who invested in Inspirna?
Inspirna has 12 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Inspirna raised?
Inspirna has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Inspirna last raise money?
Inspirna's most recent round on record is a Series D, in Jun 2022.
What does Inspirna do?
Inspirna is a biotechnology company.
Where is Inspirna headquartered?
Inspirna is headquartered in New York, US.
Which VCs invest in companies like Inspirna?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Inspirna's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like Inspirna? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.